Darbepoetin alfa reduces cell death due to radiocontrast media in human renal proximal tubular cells
نویسندگان
چکیده
منابع مشابه
Differential activation of signaling pathways involved in cell death, survival and inflammation by radiocontrast media in human renal proximal tubular cells.
Radiocontrast media (RCM) are widely used in clinical medicine but may lead to radiocontrast-induced nephropathy (RCIN). The pathogenesis of acute renal failure secondary to RCM is not fully understood, but direct toxic effects are believed to be a major cause of RCIN. We have investigated the effect of different types of RCM on signaling pathways known to play a role in cell death, survival, a...
متن کاملMolecular Mechanisms of Renal Cellular Nephrotoxicity due to Radiocontrast Media
Modern iodinated radiocontrast media are all based on the triiodinated benzene ring with various chemical modifications having been made over the last few decades in order to reduce their toxicity. However, CIN remains a problem especially in patients with pre-existing renal failure. In vitro studies have demonstrated that all RCM are cytotoxic. RCM administration in vivo may lead to a decrease...
متن کاملNicotine-Induced Apoptosis in Human Renal Proximal Tubular Epithelial Cells
BACKGROUND Nicotine is, to a large extent, responsible for smoking-mediated renal dysfunction. This study investigated nicotine's effects on renal tubular epithelial cell apoptosis in vitro and it explored the mechanisms underlying its effects. METHODS Human proximal tubular epithelial (HK-2) cells were treated with nicotine. Cell viability was examined by using the WST-1 assay. Intracellular...
متن کاملPharmacology of darbepoetin alfa.
The distinct molecular structure of darbepoetin alfa, in both its amino acid sequence and its carbohydrate content, results in a biologic profile with lower binding affinity, longer circulating half-life, and higher in vivo potency compared with the epoetins. The mechanisms responsible for these differences in biological effects have not been fully explained. Pharmacokinetic investigations of d...
متن کاملDarbepoetin alfa (Aranesp).
BUMC PROCEEDINGS 2002;15:332–335 The Food and Drug Administration (FDA) approved darbepoetin alfa (Aranesp) for treatment of anemia as sociated with chronic renal failure (CRF) in patients on dialysis and patients not on dialysis (1). The manufacturer of the drug also filed an application with the FDA on September 18, 2001, to receive an indication for treatment of anemia in patients with cance...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Toxicology Reports
سال: 2021
ISSN: 2214-7500
DOI: 10.1016/j.toxrep.2021.03.028